Philippe Pouletty

Co-Founder, Truffle Capital

Philippe is a pioneer in the biotechnologies and medical devices sector with experience in both France and Silicon Valley.

He is the Founder and Chairman of Deinove (Alternext: ALDEI), and Abivax (Euronext: ABVX), Co-founder and Board member of Carbios (Alternext: ALCRB), Carmat (Alternext: ALCAR), Biokinésis, Pharnext,  Vexim (Alternext: ALVXM), Board member of Myopowers, Kephalios, Symetis, Theraclion (Alternext: ALTHE), Theradiag (Alternext: ALTER) and Altimmune, all of which are Truffle Capital portfolio companies.

Philippe is an independent board member of Innate Pharma (Euronext). Before co-founding Truffle, Philippe founded SangStat (1988, therapeutic for organ transplants, listed on NASDAQ in 1993, sold to Genzyme for USD 600M in 2002), and Conjuchem (founded in 1993, listed on the Toronto Stock Exchange in 2000). He is also the former Chairman (2001-2009) and current Honorary Chairman of France Biotech, the French biotech industry association and former Vice Chairman of Europabio, the European biotech industry association. He conceived the Young Innovative Entreprise Status (JEI), which was implemented in France by President Chirac in 2004.

He is the inventor of 29 patents, including the second highest revenue generating life science patent for Stanford University, earning him entry into the prestigious Stanford University Hall of Fame of Inventors in 2012. He was also awarded the Chevalier of the Légion d’Honneur.

Educational qualifications: A former hematology and immunology resident in Parisian hospitals, Dr. Pouletty holds an MD from the University of Paris VI and Master’s in immunology and virology from l’Institut Pasteur, was a post-doctoral research fellow (1986-1988) at Stanford University, and the 1999 laureate of the American Liver Foundation.